Polyclonal immunoglobulins in malignant plasma cell dyscrasias

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Malignant plasma cell dyscrasias (PCD) encompass conditions like multiple myeloma (MM) and solitary myeloma (SM).
• Polyclonal immunoglobulin (Ig) levels can be affected by the progression of PCD.

Purpose of the Study:

• To investigate the diagnostic and prognostic value of polyclonal immunoglobulin measurements in patients with malignant PCD.
• To correlate Ig levels with disease burden and treatment response in MM and SM.

Main Methods:

• Measurement of polyclonal immunoglobulins (IgA, IgG, IgM) at diagnosis and post-chemotherapy.
• Correlation of Ig levels with myeloma cell burden and treatment outcomes in 226 patients (215 MM, 11 SM).

Main Results:

• Significant Ig synthesis suppression observed in 80.7% of MM patients at diagnosis, but not in SM patients (p < 0.001).
• Correlation found between IgA/IgM levels and myeloma cell burden in MM patients (p < 0.01).
• Increased Ig levels post-chemotherapy were associated with >90% myeloma cell mass regression and a ≥1-year plateau period.

Conclusions:

• Polyclonal immunoglobulin evaluation is a valuable tool for diagnosing and predicting the prognosis of malignant PCD.
• Ig levels serve as indicators of disease burden and treatment efficacy in patients with MM and SM.